ReviewAAPS PharmSciTech2026
Delivery Strategies and Clinical Significance of Oral Colon-targeted Drug Delivery Systems.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pharmacomicrobiomics-driven targeted drug delivery for precision microbiome modulation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Colon-Specific Delivery of Febuxostat via an Amino Acid Conjugate Enhances Anti-Colitis Efficacy and Limits Systemic Exposure.Pharmaceutics · 2026Article
- Colon-targeting pH-responsive Bletilla striata polysaccharide coacervate microdroplets for ulcerative colitis therapy via macrophage reprogramming.Journal of nanobiotechnology · 2026Article
- Development of pH-Dependent Magnetically Actuated Millirobot for Colon-Targeted Delivery of Diverse Drug Types.Micromachines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Formulation strategies for colonic delivery offer a unique opportunity for the local delivery of drugs for symptomatic relief in inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and colorectal cancer, as well as for the systemic delivery of peptides and biologics. By releasing active pharmaceutical ingredients (APIs) directly at the site of action within the colon, these systems can achieve higher local exposure with reduced systemic effects. This is achieved by utilizing prodrugs, pH-sensitive polymers, time-dependent systems, pressure, microbiota, and multi-pronged systems. Monolithic delivery systems can deliver drugs to the colon with limitations; however, the multiparticulate drug delivery of pellets has proven to be a superior methodology in meeting targets. This review highlights various techniques to bypass the upper part of the gastrointestinal tract, thereby releasing the active pharmaceutical ingredient specifically in various parts of the intestine and colon, to achieve both local and systemic therapeutic effects.
Indexed as
Identifiers
41617917What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.